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Summary
There are many transgenic GFP reporter lines that allow visualization of specific populations of 
cells. Using such lines for functional studies requires a method that transforms GFP into a 
molecule that enables genetic manipulation. Here we report the creation of a method that exploits 
GFP for gene manipulation, Cre Recombinase Dependent on GFP (CRE-DOG), a split component 
system that uses GFP and its derivatives to directly induce Cre/loxP recombination. Using plasmid 
electroporation and AAV viral vectors, we delivered CRE-DOG to multiple GFP mouse lines, 
leading to effective recombination selectively in GFP-labeled cells. Further, CRE-DOG enabled 
optogenetic control of these neurons. Beyond providing a new set of tools for manipulation of 
gene expression selectively in GFP+ cells, we demonstrate that GFP can be used to reconstitute 
the activity of a protein not known to have a modular structure, suggesting that this strategy might 
be applicable to a wide range of proteins.
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Introduction
A challenge to the understanding of brain function is the ability to monitor and/or 
manipulate the activity of the many different cell types comprising the nervous system. To 
label specific cell types, many transgenic reporter lines using Green Fluorescent Protein 
(GFP)1, 2 as a marker of gene expression3 have been generated for various model organisms. 
Notably, over 1,000 transgenic GFP mouse lines are now characterized for labeling specific 
cell populations in the central nervous system (gensat.org)4–6. Until recently, GFP lines have 
been used only for labeling purposes. However, studies probing cellular function often 
require genetic manipulations, e.g. using mouse lines expressing site-specific DNA 
recombinases in specific cell types to drive the expression of, or deletion of, particular 
genes. Compared to GFP reporter lines, the availability of mouse lines expressing the widely 
used Cre recombinase in specific cell types is more limited, and Cre expression patterns 
have not been as extensively characterized (gensat.org and Allenbrain.org). Manipulation of 
GFP-labeled cell types previously required the generation of new mouse lines, e.g. using the 
same cis-regulatory sequences that drove GFP in specific cell types in order to drive Cre 
expression in the same cell types. For more complex model organisms such as the mouse, 
such an approach is costly and time-consuming. Furthermore, the expression pattern of Cre 
in these lines could differ from that of the equivalent GFP reporter line, potentially due to a 
combination of high sensitivity of Cre and/or position effects exerted by neighboring 
genomic sequences.
Recently, we developed GFP-dependent transcription factors (T-DDOGs) that enable 
retrofitting of transgenic GFP lines for functional manipulation studies7. In this system, GFP 
acts as a scaffold, bringing together modular transcription domains to assemble a hybrid 
transcription factor for activation of a target gene of interest. GFP recognition is mediated by 
pairs of GFP binding proteins (GBPs), derived from the antigen recognition portion of 
camelid antibodies8, 9. These “nanobodies” are easily expressed in living cells and can be 
used as fusion proteins7–10. T-DDOGs opened the door for quick genetic manipulation of 
GFP-labeled cells via DNA electroporation, bypassing the need to generate transgenic Cre 
lines for cell-specific gene manipulations in certain cases7.
Several reasons motivate the continued development of new GFP-dependent systems. First, 
unlike transcription factors11, 12, many proteins such as enzymes are not composed of simple 
modular structures. It is unclear whether GFP can be used to directly control the activity of 
such non-modular proteins. Second, many genetic tools depend on the action of Cre 
recombinase. Although T-DDOG can induce Cre expression, this effect requires the action 
of three genetically encodable components. While electroporation can efficiently deliver 
multiple plasmids encoding T-DOGG to single cells, this approach is restricted to certain 
tissues and developmental time points. In contrast, the popular recombinant adeno-
associated viral (rAAV) vectors can efficiently deliver multiple transgenes to single cells, 
across diverse tissues and over different developmental and/or mature stages. rAAVs 
encoding the recombinase-dependent flip-excision (FLEX) switch further enables 
convenient and selective expression of transgenes in specific cell types when injected into 
transgenic Cre and/or Flp lines13–15. The integration of GFP-inducible systems with FLEX 
responder genes in a rAAV delivery scheme would provide a simple protocol for rapid 
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manipulation of many types of genes selectively in GFP-labeled cell types. Furthermore, 
such a method would increase the number of specific cell types that could be manipulated 
with intersectional approaches, as transgenic animals with a combination of GFP plus Flp in 
specific cell types could activate transgenes that are Cre plus Flp-dependent14, 16.
Here, we successfully used GFP to control the activity of Cre, in the form of split Cre-GBP 
fusion proteins that together make up Cre Recombinase-Dependent On GFP (CRE-DOG). 
The GBP-Split Cre fusion proteins assemble as a complex on the GFP scaffold, initiating 
Cre recombination (Fig.1a). This system only requires two components for direct activation 
of Cre recombination (Supplementary Fig.1). We generated rAAV reagents that enable 
delivery of CRE-DOG to diverse tissues and brain regions that cannot be electroporated, for 
rapid and tight GFP-regulated Cre-dependent transgene expression across GFP reporter lines 
and cell types. To demonstrate the utility of this approach, we showed that CRE-DOG can be 
used for optogenetic manipulation of GFP-expressing cells in the nervous system.
Results
CRE-DOG refers to the combined action of two chimeric proteins bearing complementary 
split Cre fragments17 each fused to a different GBP. We tested the GBP1+GBP6 and 
GBP2+GBP7 combinations, as they had been previously used to assemble a hybrid 
transcription factor on the GFP scaffold in living cells7. Using a CAG-loxP-Neo-loxP-luc2 
(CALNL-luc2) construct, (or “floxed” luciferase reporter), we screened pairs of the GBP-
split Cre fusion proteins for GFP-dependent activity. Almost all GBP-split Cre pairs had 
either low GFP-induced recombination activity or high background activity (data not 
shown). We considered whether it is possible to increase efficiency by generating a full-
length Cre recombinase via protein splicing18. To this end, we inserted the artificially split S. 
cerevisiae vacuolar ATPase (VMA1) intein elements19, 20 into the GBP-split Cre constructs 
and conducted additional reporter screens. None of the constructs based on the GBP1+GBP6 
pair yielded any high efficiency recombination. However, a subset of constructs based on the 
GBP2+GBP7 combination gave the desired GFP-dependent Cre activity with reasonably low 
background activity. The most desirable pair of fusion constructs showed strong GFP-
dependent recombination activity in vitro and in vivo, and was named CRE-DOGOG 
(Supplementary Fig. 2). CRE-DOGOG refers to the combined action of two fusion protein 
components, N-CreintG and C-CreintG. In contrast to the T-DDOG system, which carries 
the caveat of being potentially toxic to cells as a consequence of the squelching phenomenon 
caused by transcription activation domains21, CRE-DOGOG did not induce any noticeable 
abnormality in retinal cells.
Although intein elements were intended to create a Cre protein via protein splicing, we 
failed to find evidence supporting this mechanism in several tests (Supplementary Fig. 3). To 
promote protein splicing, the split-intein of VMA1 requires a cysteine residue at the 
boundary between each split-intein and its respective fusion partner22. Double alanine and 
double serine substitutions at the cysteine positions were expected to disrupt protein 
splicing22, but were found to have little adverse effect on the GFP-specificity or efficiency of 
CRE-DOGOG22(Supplementary Fig. 3a). Second, each split VMA element promoted GFP-
specificity even in the absence of its protein splicing partner (Supplementary Fig. 3b). Third, 
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under conditions in which GFP could induce the activity of a FLAG-tagged CRE-DOGOG 
variant, we failed to detect the appearance of spliced, full-length Cre in the presence of GFP 
(Supplementary Fig. 3c–d). Nonetheless, as these combined fusion proteins provided a more 
active GFP-dependent Cre, we continued to optimize these constructs.
Although CRE-DOGOG gave GFP-dependent recombination in vitro and in vivo, 
background activity in the absence of GFP did accumulate noticeably over time in vitro 
(data not shown). Thus, we conducted additional screens to further optimize CRE-DOGOG 
activity. We found that the 184 aa N-terminal portion of VMA (N-VMA) could be further 
truncated without adversely affecting CRE-DOG activity. Serial residue deletion and 
insertion scans along N-VMA led to the isolation of a 43 aa truncated element that promoted 
both enhanced GFP-dependent recombination and reduced GFP-independent activity when 
compared to CRE-DOGOG (Supplementary Fig. 4–5, Supplementary Table 1). This 
truncated fusion protein, hereafter named N-CretrcintG, was combined with C-CreintG to 
give the Optimized CRE-DOG (CRE-DOGOPT) (Fig. 1b). CRE-DOGOPT activity depended 
upon all components of the system and was specific for GFP and its derivatives (Figs. 1c,d). 
Further, CRE-DOGOPT activity was dependent upon GFP dosage in a manner similar to that 
observed for T-DDOGs7 (Fig. 1e).
We next tested whether CRE-DOG could retrofit existing transgenic GFP reporter lines for 
cell type-specific manipulations. The Tg(CRX-GFP) line expresses GFP strongly in 
photoreceptors and weakly in inner nuclear layer (INL) cells23. Tg(CRX-GFP) retinas 
electroporated with CRE-DOGOPT and CALNL-DsRed plasmids showed strong DsRed 
labeling of photoreceptors and occasional labeling of INL cells, whereas electroporated 
retinas that were GFP-negative showed little to no DsRed expression (Figs. 2a,b, 
Supplementary Fig. 6a-c). Additionally, 100 +/− 0 % (hereafter mean +/− s.d) of DsRed 
cells labeled in the outer nuclear layer (ONL) were GFP+ (Supplementary Fig. 6g). CRE-
DOGOPT induced DsRed expression in 76 +/− 4% of electroporated cells in the ONL 
(Supplementary Fig. 6a). This is an estimate of CRE-DOGOPT efficiency in vivo as all 
electroporated cells in the ONL were GFP+. The value is likely an underestimate of 
efficiency, as it has not been corrected for the percentage of cells that were co-electroporated 
with all constructs.
As a considerable retinal diversity lies within the bipolar cell class, we tested whether CRE-
DOGOPT would be effective in this cell class. We used a bipolar-selective promoter (ChAG) 
to drive strong expression of CRE-DOGOPT components in various bipolar cell types of the 
Tg(PROX1-GFP) line, and assayed Cre activity with a ChAG-loxP-TagBFP-loxP-mCherry 
reporter (ChAG-LtBFPL-mCherry). In contrast to Tg(CRX-GFP), electroporated 
Tg(PROX1-GFP) retinas showed strong mCherry labeling of bipolar cells, as well as sparse 
labeling of photoreceptors, and rare labeling of Müller glia and amacrine cells (Fig. 2c). 
Although only 83 +/− 10% of mCherry+ cells were GFP+ (Supplementary Fig. 6g), analysis 
of electroporated GFP-negative retinas indicated that the system was absolutely GFP-
dependent (Fig 2c and Supplementary Fig. 6d,e). Thus, developmental expression of 
Tg(PROX1-GFP) in progenitor cells giving rise to multiple cell classes, or weak/transient 
GFP expression, may contribute to the labeling pattern. These results establish the utility of 
CRE-DOG for genetic manipulation of specific cell types in transgenic GFP animals.
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rAAV are widely-used vectors for delivering transgenes to the mammalian nervous system, 
due to their high infectivity of postmitotic neurons and low toxicity24. The ability to deliver 
rAAV-encoded CRE-DOGOPT along with rAAV carrying the tight Cre-responsive FLEX 
switch13 in a single injection mixture would provide a fast and versatile approach for 
manipulating genes in GFP-labeled cell types across wide areas of the nervous system and 
across a broad age window. Indeed, rAAV-encoding CRE-DOGOPT could be used to turn on 
rAAV-FLEX-tdTomato (tdT) in a GFP-dependent manner in vivo (Supplementary Fig. 7a). 
To test this approach in transgenic GFP lines, we co-injected rAAV-CRE-DOGOPT and 
rAAV-FLEX-tdT into retinas of Tg(TRHR-GFP)25 and Tg(CDH3-GFP)26 lines, both of 
which express GFP in specific retinal ganglion cell (RGC) subtypes. Functional studies of 
RGCs have been hampered by the scarcity of Cre driver lines that are selectively active in 
the same RGC subtypes seen in multiple GFP reporter lines. Single injection of the 
aforementioned rAAV mixture into GFP-negative retinas resulted in no detectable tdT 
expression in Cre immunopositive cells of the ganglion cell layer (GCL) (0 tdT+ cells in 140 
anti-Cre+ cells, sampled across 3 retinas; Supplementary Fig. 7b). In contrast, we found 
highly selective tdT expression in GFP+ RGCs, with 89 +/− 7% of tdT+ cells being TRHR-
GFP+ (207 of 243 tdT+ cells, 5 retinas) and 85% of tdT+ cells being CDH3-GFP+ (11 of 13 
tdT+ cells, 2 retinas) (Fig. 3a,b) (data not shown for Tg(CDH3-GFP)). The sparser number, 
as well as nonuniform spatial distribution of CDH3-GFP+ RGCs, may possibly contribute to 
the low number of cells labeled by tdT27. Importantly, strong tdT expression enabled tracing 
of labeled RGC projections into various brain targets; the resultant patterns were consistent 
with the identity of GFP+ RGCs previously characterized for Tg(TRHR-GFP) 25 (Fig. 3c,d). 
Taking the rAAV and electroporation results together, we have shown that one can use CRE-
DOGOPT to selectively target GFP cells residing in all three major cellular layers of a neural 
tissue, the retina.
To evaluate whether CRE-DOG is useful outside the retina, we co-injected rAAV-CRE-
DOGOPT and rAAV-FLEX-tdT into additional neural tissues. We targeted GFP cells of the 
spinal cord in the Tg(CBLN2-GFP) line4, which expresses GFP in a subset of interneurons 
in the dorsal horn (unpublished data, VEA) (Fig. 4a). While rAAV infection of wildtype 
spinal cords did not result in detectable tdT expression (0 tdT+ out of 108 anti-Cre+ cells, 
sampled from 2 spinal cords), infection of Tg(CBLN2-GFP) spinal cords led to the 
appearance of tdT+ cells, some of which expressed tdT at levels strong enough for process 
visualization (Fig. 4b–c). 75% of tdT+ cells were detected to be GFP+ (n=105 tdT+ cells, 
sampled from 2 spinal cords). Thus, the labeling pattern may include cells that had transient 
and/or low levels of GFP, below the detection threshold. To estimate the efficiency of rAAV-
CRE-DOGOPT gene manipulation protocol in the spinal cord, we quantified the number of 
tdT+ cells among the GFP+ cells that also expressed split-Cre fragments, as detected by a 
polyclonal Cre antibody. Using this approach, we estimate the efficiency to be 51% (n=37 
Cre+, GFP+ cells, sampled from 2 spinal cords).
We also tested for CRE-DOGOPT activity in the brain. The Tg(GAD67-GFP) line expresses 
GFP in GABAergic cell types in multiple brain regions28. We injected the rAAV mixture 
encoding CRE-DOGOPT and FLEX-tdT into the motor cortex as well as into the cerebellum 
of Tg(GAD67-GFP) animals (Fig 5 and 6, Supplementary Table 2). Cortical infection 
resulted in GFP-dependent induction of tdT expression throughout all cortical layers of 
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Tg(GAD67-GFP) brains (Fig. 5b–d). A high percentage of tdT+ cells was GFP+, at 98 +/
− 2 % (Fig.5b). In addition, 78 +/− 10% of GFP+ and anti-Cre+ cells were also tdT+, 
providing an estimate of efficiency of the rAAV-CRE-DOGOPT injection protocol in the 
brain (Fig 5b). Remarkably, despite efficient infection of cortical pyramidal neurons as 
evidenced by Cre immunostaining, no pyramidal neurons and rarely any other cell type were 
tdT+ in GFP-negative mice (8 tdT+ cells in 2560 anti-Cre+ cells, 10 sections, 2 GFP-
negative brains; Fig. 5d and Supplementary Table 2). Injection of the rAAV-CRE-DOGOPT 
and FLEXT-tdT mixture into Tg(GAD67-GFP) cerebella resulted in strong GFP-dependent 
labeling of multiple GABAergic cerebellar cell types, including Purkinje cells (PCs), 
molecular layer interneurons (MLIs) and granule layer interneurons (GLIs), as confirmed by 
morphology and immunostaining for cell type markers (Fig. 6, Supplementary Figs.8 and 9, 
Supplementary Table 2). Anti-Cre staining demonstrated little to no CRE-DOGOPT activity 
in GFP-negative cerebella infected with the rAAV mixture (Fig. 6c–d, Supplementary Figs.8 
and 9e–g, Supplementary Table 2). In infected Tg(GAD-GFP) cerebella, we found that 96 +/
− 2 % of tdT+ cells were GFP+, and in areas of dense infection, 42 +/− 10 % of all GFP+ 
cells were tdT+ (Fig. 6e). To more accurately evaluate the efficiency of the CRE-DOGOPT 
system, we quantified the percentage of tdT+ cells that were both anti-Cre+ and GFP+, 
which was 55 +/− 26 % and ranged between 44–67% depending upon cell type (Fig. 6d, 
Supplementary Table 2).
To evaluate the utility of CRE-DOGOPT for functional studies, we co-infected Tg(GAD67-
GFP) with rAAV-CRE-DOGOPT and rAAV-FLEX-ChR2-tdT for optogenetic manipulations 
in GFP+ cells (Fig 7a–c). We were able to directly trigger light-evoked action potentials and 
photocurrents in ChR2-tdT-labeled PCs (n=9) and MLIs (n=6) (Fig. 7d,e). We also were able 
to optogenetically inhibit spontaneous activity in ChR2-tdT-negative PCs that received 
GABAergic synaptic input from ChR2-tdT+ MLIs (n=4) (Fig. 7f). GFP+ PCs in uninfected 
areas, as well as PCs in infected areas of GFP-negative littermates, did not show any light-
induced photocurrents or light-triggered synaptic currents (n=9 for GFP-negative animal, 
n=8 in uninfected area) (Fig. 7g). Finally, infected PCs and MLIs did not differ from 
uninfected cells in intrinsic electrical properties, assessed by membrane resistance and 
spontaneous action potential frequency (p=0.92 and 0.73, respectively, One-way ANOVA for 
PCs, and p=0.87 and p=0.81, respectively, t-test, for MLIs) (Fig. 7h,i). Together, these 
results demonstrate the utility of CRE-DOG for cell-specific manipulation of neural circuit 
activity in the brain.
Discussion
Here, we developed a high signal-to-noise system, CRE-DOGOPT, that provides a reliable 
and rapid means of genetically manipulating GFP-expressing cells in the many GFP lines 
available for life science research. We demonstrate the repurposing of GFP reporter lines for 
cell-specific gene manipulation via electroporation and/or viral infection. Given the 
widespread use of rAAVs among neuroscientists, rAAV-encoded CRE-DOGOPT should 
immediately be useful for many neuroscience applications. rAAV allows delivery over a 
broader time window and into more tissues than electroporation, the method originally used 
to deliver T-DDOG. It should be straightforward to apply rAAV-encoded CRE-DOGOPT in a 
single injection mixture with rAAV-encoded Cre-dependent transgenes, or into transgenic 
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GFP animals with Cre-responsive alleles. Further refinement in cell targeting should be 
possible by intersecting GFP-dependent CRE-DOGOPT activity with other recombinases in 
intersectional strategies14, 16
The CRE-DOGOPT-encoding plasmids described here also will be immediately useful for 
targeting GFP cells for gene manipulation via electroporation. The electroporation approach 
holds an advantage over rAAV delivery in that it is not limited by virus packaging size. This 
can be exploited in several ways, including the delivery of larger Cre-dependent transgenes 
and/or larger cis-regulatory elements controlling expression pattern of CRE-DOGOPT and/or 
Cre-dependent transgenes.
We tested CRE-DOGOPT in multiple neural tissues in vivo and found that its activity was 
highly dependent on GFP expression. Importantly, the engineered split Cre components 
retain the ability to induce recombination of responder cassettes in the popular “floxed” and 
“FLEXed” configurations. In multiple tests described here, CRE-DOGOPT was capable of 
inducing strong fluorescent reporter protein expression, allowing for visualization of fine 
neuronal processes for morphological and axonal tracing analysis either with unstained or 
immunostained tissues (Fig. 2–7 and Supplementary figures 7 and 9). Optogenetic control of 
specific cell types is a powerful means of dissecting the function of cells within neural 
circuits29. We showed that CRE-DOGOPT could convert GFP expression into ChR2 
expression for cell type-specific and temporally precise manipulation of neural activity (Fig. 
7). Beyond light-activated ion channels, many other genetically encodable tools have been 
developed to uncover the anatomical and physiological features of neurons29–33. We 
anticipate CRE-DOGOPT to enable activation of any one, or a combination of these readily 
available tools in any cell type labeled with GFP.
As with any exogenous construct, the efficiency of CRE-DOGOPT depends upon the 
effectiveness of gene delivery. We found CRE-DOGOPT to be active in ~44–78% of cells 
receiving electroporated plasmids or virally delivered CRE-DOGOPT components in vivo. 
These numbers are likely underestimates of the true efficiency, as we could not completely 
focus our analysis on cells that received the complete set of CRE-DOGOPT components. For 
example, rAAV infected cells with only one Cre-fusion protein, or cells with both CRE-
DOGOPT components but not FLEX-tdT, would be included in the population of tdT-
negative cells. To increase efficiency, it may be beneficial to encode both CRE-DOGOPT 
components in a single plasmid or rAAV vector, perhaps by linking the two components in a 
bicistronic cassette. In addition, transgenic lines expressing the two components in a 
bicistronic cassette would provide activation in a large number of GFP-labeled cells through 
the use of genetic crosses. Another consideration when using rAAV is the serotype and the 
promoter used to drive each CRE-DOGOPT component, as different serotypes and promoters 
may promote differential expression patterns. Such differences are not necessarily a 
problem. Instead, they may be exploited for intersectional targeting of CRE-DOGOPT 
activity, for precise cell-specific manipulations16. For example, two different promoters may 
be used to express each of the CRE-DOGOPT components, resulting in Cre activity in a 
subset of GFP-expressing cells. Alternatively, it may be possible to intersect the spatial 
pattern of CRE-DOGOPT activity, as dictated by GFP expression, with the expression pattern 
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of other site-specific recombinases and/or transcription factors, using dual or multiple input-
responsive cassettes14, 16, 34.
Both CRE-DOGOPT or T-DDOG may now be used for manipulation of GFP-expressing 
cells. Several considerations influence the choice of one versus the other. First, over-
expression of transcription activation domains may cause undesirable side effects. We found 
this to be the case for T-DDOG variants using particularly potent activation domains, and 
overcame the issue by changing the activation domain7. Unlike transcription factors, Cre 
recombinase does not depend on interactions with endogenous cellular machinery and may 
be expected to induce fewer complications. Indeed, we did not detect any abnormalities in 
cells overexpressing CRE-DOGOPT. This is supported by physiology tests on ChR2-
expressing cerebellar cells that failed to detect any deleterious effects (Fig. 7). However, we 
did encounter cytotoxicity when delivering the components to the cerebellum via serotype 8 
capsid, but not serotype 1 capsid (data not shown). This is thus a serotype-specific issue and 
not related to CRE-DOGOPT expression. Serotype-specific cytotoxicity has been reported 
previously and is important to consider when designing experiments35. Nevertheless, high 
levels of native Cre have been reported to be toxic in some settings36 Second, T-DDOG may 
be preferred when temporal control is desired, as T-DDOG can be modified to respond to 
drug application. It is also possible to modify CRE-DOG to confer drug inducibility, by the 
use of domains such as ERT2, or destabilizing domains37. However, this would only enable 
temporal control at the onset of expression, since Cre-mediated recombination is essentially 
irreversible.
CRE-DOGOPT, as with T-DDOG, is sensitive to high GFP levels in that GFP in excess of the 
split components can titrate out each component, thereby reducing activity. Nonetheless, 
empirically we found Cre-dependent recombination to be fairly efficient, even in lines with 
strong levels of GFP expression (Fig. 2, 5, 6). Also, CRE-DOGOPT was able to detect low 
GFP levels as demonstrated by our findings with the relatively weakly GFP-expressing RGC 
lines, which require GFP immunostaining to reveal neuronal processes (Fig. 3). In fact, we 
failed to detect GFP in some cells with evidence of recombinase activity, presumably 
because activity was triggered by GFP expression below the threshold of detection, or from 
transient GFP expression (Fig. 2, 4). This does point out that the proper control for CRE-
DOGOPT is a GFP-negative animal; we detected almost no CRE-DOGOPT activity in the 
GFP-negative tissues examined here.
The irreversibility of Cre recombination can be exploited to trigger stable expression of a 
transgene, but may also lead to accumulation of background, even if there is only low GFP-
independent recombinase activity. We did not find background activity to be an issue for the 
incubation period of 2–4 weeks used here. However, beyond this incubation period, we did 
observe increased background in rAAV-CRE-DOGOPT injected GFP-negative animals (data 
not shown). The accumulation of background may be reduced by optimizing plasmid dose or 
viral titer, and/or by using tightly drug-regulated CRE-DOGOPT variants that await 
development. Another contributor to variable background activity may be the differential 
sensitivity of Cre-responsive gene cassettes; in our experience, FLEX constructs showed less 
background recombination than loxP-STOP-loxP alleles.
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Although split intein elements were found to promote GFP-specificity of CRE-DOG, protein 
splicing did not seem to be involved. It is unclear why the inclusion of intein elements 
reduced background activity of CRE-DOG, but one could speculate that the extra elements 
influenced the orientation or conformation of the split protein fragments such that non-
specific CRE-DOG assembly was inhibited in the absence of GFP. Whether split intein 
elements would also aid in reducing background activity of other ligand-inducible split 
protein systems is an interesting issue to consider in future studies.
From a broader perspective, our work demonstrates the utility of artificially derived-binding 
proteins (ex. nanobodies, intrabodies, etc.) for constructing split enzyme systems inducible 
by intracellular proteins. The ability to rapidly isolate additional high affinity nanobodies 
should facilitate the extension of this approach to other target proteins38. Our work thus 
offers a novel approach for engineering protein-inducible systems in addition to providing a 
practical solution for retrofitting GFP reporter lines for a much broader set of applications.
Online Methods
Animals
All animal experiments performed were approved by the Institutional Animal Care and Use 
Committee at Harvard University and University of San Diego. All animals studied were 
Mus musculus. Time pregnant CD1 mice (Charles River Breeding Laboratories, Boston, 
MA) were used for electroporation experiments. Transgenic GFP mouse lines used were 
Tg(CRX-GFP)23, Tg(PROX1-GFP) (gensat.org), Tg(TRHR-GFP)25, Tg(CDH3-GFP)26, 
Tg(CBLN2-GFP) (gensat.org), Tg(GAD67-GFP)28. Strains were kept in C57BL/6 
background except Tg(CDH3-GFP), which is in FVB/N and CD1 mixed background.
Molecular Biology Reagents
Ancillary plasmids—pCAG-GFP (Addgene plasmid 11150) 39, pCAG-YFP (Addgene 
plasmid 11180) 39, pCAG-CFP (Addgene plasmid 11179) 39, pCAG-tdT (Cepko lab, 
Harvard Medical School), pCAG-mCherry (Cepko lab, Harvard Medical School), pCAG-
DsRed (Addgene plasmid 11151) 39, pRL-TK (Promega, #E2241), pRho-GFP-IRES-AP 
(referred to as Rho-GFP in main text) 40, pCAG-nlacZ (Cepko lab, Harvard Medical 
School). pAAV-CAG-FLEX-tdT was a gift from Edward Boyden (Addgene plasmid 
#28306), pCALNL-DsRed (Addgene plasmid #13769) 41.
CRE-DOG chimeric component constructs—Using standard cloning techniques, 
coding sequences of GBP1, 2, 6 and 7, the sources of which were described in Tang et al 
20137, were fused to those of split Cre and split VMA intein fragments in many possible 
configurations, and the fusion products were inserted into a pCAG vector42. Split Cre 
fragments were taken from a codon-optimized Cre coding sequence called improved Cre 
(iCre)43. Two previously described pairs of complementary split Cre fragments were tested; 
they are 1.) N-split Cre corresponding to residue 19–59 of full-length Cre (iCre19–59), 
paired with C-split Cre corresponding to residue 60–343 of full-length Cre (iCre60–343). 2.) 
N-split Cre corresponding to residue 19–104 of full-length Cre, paired with C-split Cre 
corresponding to residue 106–343 of full-length Cre17. Split VMA intein fragments, termed 
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N-terminal VMA (N-VMA or NVMA) and C-terminal VMA (C-VMA or CVMA) here, 
were described previously19 and were codon-optimized for mammalian expression by 
Genewiz (New Jersey).
Notable CRE-DOG fusion plasmids
pCAG-N-CreintG: An AgeI-Kozak-NLS-iCre19–59-NVMA-NheI restriction digested 
fragment was inserted into the backbone of AgeI/NheI digested pCAG-Gal4DBD-10gly-
GBP7 plasmid7, resulting in in-frame fusion to the 10gly-GBP7 coding sequence and 
replacing Gal4DBD in the original vector.
pCAG-C-CreintG: An NheI/NotI flanked and restriction digested fragment containing 
CVMA-iCre60–143 (C-CreintG) was inserted into the backbone of NheI/NotI digested 
pCAG-GBP2-10gly-VPminx3 plasmid7, resulting in in-frame fusion to GBP2 coding 
sequence and replacing 10gly-VPminx3 in the original vector.
pCAG-N-CretrcintG: An AgeI/NheI flanked and restriction digested fragment containing 
fusion of NLS, iCre19–59 and the last 129 bp of NVMA (N-CretrcintG) was inserted into 
the backbone of AgeI/NheI digested pCAG-N-CreintG plasmid, resulting in in-frame fusion 
to the 10gly-GBP7 coding sequence and replacing NLS-iCre19–59-NVMA in the original 
vector.
pAAV-EF1a-N-CretrcintG: A BamHI/EcoRI flanked and restriction digested fragment 
containing Kozak-N-CretrcintG was inserted into the backbone of BamHI/EcoRI digested 
pAAV-EF1a-FLEX-GTB (Addgene plasmid #26197) 44.
pAAV-EF1a-C-CreintG: A BamHI/EcoRI flanked and restriction digested fragment 
containing Kozak-C-CreintG was inserted into the backbone of BamHI/EcoRI digested 
pAAV-EF1a-FLEX-GTB (Addgene plasmid #26197) 44.
pCALNL-luc2: An EcoRI/NotI flanked and restriction digested fragment containing Kozak-
luc2 was inserted into the backbone of EcoRI/NotI digested pCALNL-DsRed (Addgene 
plasmid #13769) 41, replacing DsRed in the original vector.
pAAV-EF1a-GFP: A BamHI/EcoRI flanked and restriction digested fragment containing 
Kozak-GFP was inserted into the backbone of BamHI/EcoRI digested pAAV-EF1a-FLEX-
GTB (Addgene plasmid #26197) 44.
pAAV-EF1a-ZsGreen: A BamHI/EcoRI flanked and restriction digested fragment 
containing Kozak-ZsGreen was inserted into the backbone of BamHI/EcoRI digested pAAV-
EF1a-FLEX-GTB (Addgene plasmid #26197) 44.
pChAG-loxP-TagBFP-loxP-mCherry: First, pChAG was generated. pCAG GFP was 
digested with SpeI and SnaB1 to excise the CMV enhancer and a ~700 bp Chx10 enhancer 
element specific for bipolar cells40 was PCR amplified with flanking sequences 
corresponding to the pCAG backbone. PCR products were cloned in by Gibson assembly. To 
generate pChAG-loxP-TagBFP-loxP, pChAG was digested with AgeI and NotI. TagBFP was 
Tang et al. Page 10
Nat Neurosci. Author manuscript; available in PMC 2016 April 21.
H
H
M
I A
uthor M
an
u
script
H
H
M
I A
uthor M
an
u
script
H
H
M
I A
uthor M
an
u
script
PCR amplified using primers that had overlapping sequence with the digested vector, and 
Gibson assembly was used. To generate pChAG-loxP-TagBFP-loxP-mCherry, pChAG-loxP-
TagBFP-loxP was linearized by NotI digestion. Digested vector and amplified mCherry PCR 
product were gel purified and assembled by Gibson ligation.
pChAG-N-CretrcintG: An AgeI/NotI flanked and restriction digested N-CretrcintG 
fragment was inserted into a pChAG vector via AgeI/NotI sites.
pChAG-C-CreintG: An AgeI/NotI flanked and restriction digested C-CreintG fragment 
was inserted into a pChAG vector via AgeI/NotI sites.
CRE-DOG screens
We tested two combinations of N- and C-terminal split Cre fragments previously reported to 
be suitable for Rapamycin-induced dimerization17. A split Cre pair comprising of residues 
19–59 and residues 60–343 of full-length Cre, were each fused with the split intein portions 
from yeast VMA19 in specific orientations. These original constructs were found to give 
strong GFP-dependent recombinase activity coupled with low background activity, giving 
CRE-DOGOG. This led to additional screens optimizing for CRE-DOG activity, eventually 
giving CRE-DOGOPT. All screens were assayed with the CALNL-luc2 reporter in 293T 
cells. CRE-DOG variant components were expressed using the CAG promoter in pCAG. 
Transfected DNA of the CRE-DOG components were adjusted with filler DNA (pCAGEN) 
to ensure comparable molar DNA delivery. To assay for GFP-inducibility, pairwise 
combinations of CRE-DOG component variants were transfected into cells with pCALNL-
luc2, pRL-TK, and either pCAG-GFP or an empty CAG vector (pCAGEN). Cells were 
assayed for luciferase activity at 1 day post-transfection.
In vitro luciferase assays
Plasmids encoding CAG-driven GFP, and N- and C-terminal split Cre chimeric variants were 
transfected via polyethyleneimine (PEI) into 293T cells along with plasmids encoding 
CALNL-luc2 and pRL-TK. Between 50–70 ng of total DNA were transfected into single 
wells of 48 well plates. Cells were ~80–100% confluent at time of transfection. Cells were 
harvested 24 hours later for Dual Luciferase Assay (Promega). All transfections, except for 
the dosage curve, were done at a 1:1:1 (GFP:N-CretrcintG:C-CreintG) plasmid molar ratio. 
Both technical (pipetting of lysate into at least 2–3 different luciferase assay wells) and 
biological (at least 2–3 different transfection mixes applied to different cell culture wells) 
replicates were included in each experiment. All experimental results were verified in at 
least three independent experiments.
Western Blot
293T cells were seeded onto 6 well plates and transfected with CAG-driven N-CreintG and 
C-CreintG-FLAG, along with CAG-GFP or empty CAG vector. A CALNL-DsRed reporter 
was included in some cases to confirm GFP-dependent transfection. 24 hours post-
transfection, transfected 293T cells were lysed in RIPA buffer (150 mM NaCl, 1.0% NP40, 
0.5% Na Deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) for lysate supernatant load or 4x 
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Laemmeli buffer plus β-mercaptoethanol. Samples were run on SDS PAGE and then 
subjected to Western blot analysis. Anti-FLAG (F3165, Sigma) was used at 1:1000 dilution.
In vivo electroporations
For wildtype, Tg(CRX-GFP) and GFP-negative littermate retina electroporations, postnatal 
day 0 to 3 (P0–P3) mouse pups were electroporated in vivo as described previously7. DNA 
solutions (1–1.5 μg/μl) were injected through the sclera and into the subretinal space of the 
mouse retina. pCAGEN was used as an empty vector substitute for excluded plasmids. P0 
CD1 retinas were electroporated with plasmids encoding CAG-driven CRE-DOG 
components and CAG-driven nuclear β-galactosidase (n-βgal, an electroporation marker 
expressed from CAG-nlacZ plasmid) along with CALNL-DsRed and different promoter-
GFP constructs. Electroporated retinas were harvested at P14, immunostained for n-βgal and 
then imaged on a Zeiss LSM780 confocal microscope. For Tg(PROX1-GFP) retina 
electroporations, P2–3 Tg(PROX1-GFP) or GFP-negative littermate retinas were blindly 
electroporated with plasmids encoding ChAG-driven CRE-DOG components and ChAG-
loxP-TagBFP-loxP-mCherry; retinas were harvested between 3–4 weeks of age. Wherever 
applicable, retinas were immunostained with anti-GFP and anti-β-galactosidase.
rAAV production and injections
rAAV (serotype 2/8 or 2/1) were made from pAAV-EF1a-N-CretrcintG, pAAV-EF1a-C-
CreintG, pAAV-FLEX-tdT, pAAV-EF1a-GFP and pAAV-EF1a-ZsGreen. All rAAV, with the 
exception of rAAV-2/1-CAG-FLEX-ChR2-tdT (UPenn vector core, aliquot generously 
provided by Bernardo Sabatini lab) were generated by Chen Wang of Zhigang He’s lab 
(Boston Children’s Hospital). All rAAV were injected in the range between 1014–1015 
genome copies/ml, assayed by PCR of rAAV vectors. Primer sequences are 
GACCTTTGGTCGCCCGGCCT and GAGTTGGCCACTCCCTCTCTGC, which target the 
ITR region of rAAV vectors.
For Supplementary Figure 9, rAAV-2/8-EF1a-N-CretrcintG, rAAV-2/8-EF1a-C-CreintG and 
rAAV-2/8-FLEXtdT were co-injected with rAAV-2/8-EF1a-GFP or rAAV2/8-EF1a-ZsGreen 
into P0 mouse retina. Injected retinas were harvested in adulthood, between P21–30.
For Tg(TRHR-GFP) and Tg(CDH3-GFP) rAAV experiments, retinas were injected with 
rAAV-2/8 or rAAV-2/1 individually encoding N-CretrcintG, C-CreintG and FLEX-tdT into 
P4 or 2–3 month old animals. 2–4 weeks post-infection, retina and brain sections were 
processed as described previously45–47. A brief description is provided in the histology 
section.
For rAAV infection of the spinal cord, P21 Tg(CBLN2-GFP) mice and GFP-negative 
littermates of either sex aged were anesthetized with a continuous level of 2% isoflurane. A 
total volume of 400 nl of the following viral constructs: rAAV2/1-EF1a-N-CretrcintG, 
rAAV2/1-EF1a-C-CreintG, rAAV2/1-FLEX-tdT was injected over four injection sites 
between vertebrae L3–L5. 4 weeks later, lumbar spinal cord tissue was collected for 
immunohistochemistry.
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For rAAV infection of cerebellum and the cortex, Tg(GAD67-GFP)+ mice and GFP-
negative littermates of either sex aged 3–4 weeks were anesthetized with ketamine/xylazine/
acepromazine at 100, 2.5 and 3 mg/kg, respectively, and a continuous level of deep 
anesthesia was maintained with 5% isoflurane. A total volume of 200 nl of the following 
viral constructs: rAAV-2/1-EF1a-N-CretrcintG, rAAV-2/1-EF1a-C-CreintG, rAAV-2/1-
FLEX-tdT, or rAAV-2/1-CAGGS-FLEX-ChR2-tdT.WPRE.SV40 was injected into 
cerebellar lobule V or motor cortex using a stereotactic device. 3 weeks later, brain tissue 
was fixated for immunohistochemistry, or prepared for electrophysiology.
Histology
Retinal immunohistochemistry—Isolated mouse retinas were fixed at room 
temperature for 30 minutes in 4% paraformaldehyde/PBS solution. Retinas were then 
transferred to 30% sucrose in PBS, and subsequently into a 50/50 mixture of 30% 
sucrose/PBS and OCT for sectioning. 20–25 μm retinal cryosections were cut on a Leica 
CM3050 cryostat (Leica Microsystems), using disposable blades. Retinal cryosections were 
incubated in blocking solution (5% normal donkey serum, 0.1% Triton-X in PBS) for 1 hour 
and stained for primary antibody overnight at 4 °C. Immunostained cryosections were 
washed three times in 0.1% Triton-X in PBS and stained for secondary antibodies in 
blocking solution for 2 hours at room temperature. Slides were then washed in 0.1% Triton-
X in PBS and mounted for imaging in Fluoromount-G (Southern Biotechnology Associates; 
0100-01). Retinal sections were taken on a Zeiss LSM780 confocal microscope. Slides were 
scanned using a 40x or 63x oil immersion objective.
For rAAV infected transgenic GFP retinas, mice were transcardially perfused with 1xPBS 
followed by 4% PFA. Eyes were fixed in 4% PFA for 3–4 hours and retinas dissected and 
rinsed in 1xPBS. Retinas were incubated for 2 hours in blocking solution (10% goat serum, 
0.25% Triton-X, 1x PBS) at room temperature followed by incubation with block solution 
containing primary antibodies at 4 °C overnight. Tissue was washed in 1x PBS (3×, 30 min). 
Retinas were incubated in block solution containing secondary antibody for 2 hours at room 
temperature, and washed in PBS (3×, 30 min). Then, retinas were mounted and cover 
slipped with Vectashield containing DAPI (Vector Laboratories) and then imaged using 
either an epifluorescent Zeiss Axio Imager 2 or a Zeiss LSM 780 confocal microscope47.
Spinal cord immunohistochemistry—Mice were transcardially perfused with 4% PFA 
in PBS (pH=7.4) and the spinal cord was post-fixed overnight at 4 °C in the same solution. 
Sagittal slices of the lumbar spinal cord were cut at 50 μm thickness on a Leica VT1000S 
vibratome. Free-floating sections were immunostained using standard methods for spinal 
cord histology (for a detailed protocol see reference48). Stained slices were then mounted on 
Superfrost plus slides (VWR) with Fluoromount-G (SouthernBiotech). Images were 
acquired with an LSM700 confocal microscope.
Cerebellar immunohistochemistry—Mice were transcardially perfused with 4% PFA 
in PBS (pH=7.4) and the brain was post-fixed overnight at 4 °C in the same solution. 
Parasagittal vermal slices of the cerebellum were cut at 40 μm thickness on a Leica 
VT1000S vibratome. Free-floating sections were immunostained using standard methods. 
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Slices were then mounted on Superfrost slides (VWR) using Prolong Diamond mounting 
medium (Invitrogen). Images were acquired with an Olympus FV1000 or FV1200 confocal 
microscope. Whole brain sections were imaged on an Olympus MVX10 MacroView 
dissecting scope.
Antibodies and stains
For immunohistochemistry of retinas: rabbit anti-GFP (1:500 dilution) (A-6455, Invitrogen), 
chicken anti-β-galactosidase (1:1000 dilution) (ab9361, Abcam), rabbit anti-TagRFP 
(1:1000) (AB233, Evrogen). Note that anti-TagRFP also recognizes TagBFP and shows 
cross-reactivity to mCherry. The mCherry cross-reactivity did not cause problems for our 
analysis. In fact, it was advantageous in our identification of electroporated cells in the 
Tg(PROX1-GFP) experiment. Secondary antibodies raised against the relevant species were 
obtained from Jackson ImmunoResearch or Invitrogen.
For immunohistochemistry of rAAV-infected transgenic GFP retinas: rabbit anti-DsRed 
(1:2000 dilution) (632292, Clontech), chicken anti-GFP (1:2000 dilution) (1020, Aves Labs 
Inc).
For spinal cord immunohistochemistry: chicken anti-GFP (1:1000 dilution) (1020, Aves 
Labs Inc), rabbit anti-DsRed (1:1000 dilution) (632292, Clontech). rabbit anti-Cre (1:200 
dilution) (69050-3, Novagen) Isolectin GS-IB4 (AlexaFlour conjugated, Molecular Probes, 
1:500)
For cerebellar and cortical immunohistochemistry: chicken anti-GFP (1:200 dilution) 
(ab13970, Abcam), rabbit anti-Calbindin (1:500 dilution) (AB1779, Millipore), rabbit anti-
Parvalbumin (1:1000 dilution) (PV25, Swant), rabbit anti-Cre (1:200 dilution) (69050-3, 
Novagen). Secondary antibodies: goat anti-rabbit and chicken anti-rabbit coupled to Alexa 
647 (A-21443 and A21245, Invitrogen).
Slice preparation for electrophysiology
Mice were anaesthetized with isoflurane and decapitated. The brain was quickly removed 
and immersed in oxygenated ice-cold cutting solution containing (in mM) 110 choline 
chloride, 25 glucose, 25 NaHCO3, 11.5 sodium ascorbate, 7 MgCl2, 3 sodium pyruvate, 2.5 
KCl, 1.25 NaH2PO4, 0.5 CaCl2. Parasagittal cerebellar slices were cut at 270 μm thickness 
on a Leica VT1200S and subsequently allowed to recover for 30 min at 32 °C in ACSF 
equilibrated with 95% O2 and 5% CO2, containing (in mM) 125 NaCl, 26 NaHCO3, 1.25 
NaH2PO4, 2.5 KCl, 1, MgCl2, 2 CaCl2, and 25 glucose. Slices were then kept at room 
temperature for up to 5 hours.
Electrophysiological recordings
Slices were superfused with 31–32 °C warm ACSF at a flow rate of ~3 ml/min in a 
recording chamber heated by an inline heater (Warner instruments). PCs and MLIs were 
visualized using an Olympus BX51WI microscope equipped with differential interference 
contrast (DIC). GFP+ and ChR2-tdT+ were imaged using a custom two-photon laser-
scanning microscope with 750 nm illumination49. Visually guided recordings were 
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performed with ~2 MΩ (PCs) and 3.5 MΩ (MLIs) borosilicate glass pipettes (Sutter 
Instrument). The internal solution for voltage-clamp recordings contained the following (in 
mM): 140 Cs-methanesulfonate, 15 HEPES, 0.5 EGTA, 2 TEA-Cl, 2 MgATP, 0.3 NaGTP, 
10 phosphocreatine-tris2, and 2 QX 314-Cl (pH adjusted to 7.2 with CsOH). For current-
clamp recordings the internal solution contained 150 K-gluconate, 3 KCl, 10 HEPES, 0.5 
EGTA, 3 MgATP, 0.5 GTP, 5 phosphocreatine-tris2, and 5 phosphocreatine-Na2 (pH 
adjusted to 7.2 with KOH). Recordings were performed with a 700B Axoclamp amplifier 
(Molecular Devices) and were controlled with custom software written in Matlab 
(generously provided by Bernardo Sabatini, Harvard Medical School). ChR2-tdT+ cells 
were excited using a 473 nm wavelength blue laser (OptoEngine) coupled through the 
excitation pathway of the microscope. Laser light was focused onto slices through a 40× 
water-immersion objective. Brief light pulses (0.5–1 ms) at an intensity of 3–5 mW/mm2 
evoked ChR2-mediated photocurrent and stimulus-locked action potentials.
Data analysis
Imaging data was analyzed and processed with ImageJ (National Institutes of Health, 
Bethesda, MD), Imaris (Bitplane, Zurich, Switzerland), ZEN (Carl Zeiss Microscopy, 
Göttingen, Germany) and/or Photoshop (Adobe Systems, Mountain View, CA) software. 
Prism (GraphPad, La Jolla, CA) was used to generate graphs. Electrophysiological data was 
analyzed with IgorPro (Wavemetrics, Lake Oswego, OR), AxographX (Axograph Scientific, 
Sydney, Australia) and Prism (GraphPad, La Jolla, CA). For luciferase assays, two-tailed 
Student’s t test assuming unequal variance was used for all comparisons. p > 0.05 is judged 
as statistically significant. For cerebellar data, statistical significance was assessed with two-
tailed Student’s t test (Fig. 7i) assuming unequal variance or One-way ANOVA (Fig. 7h). 
Statistical significance was assumed when p<0.05.
Quantifications
Quantification of cells was performed on the imaging software ZEN (Zeiss) or ImageJ 
(National Institutes of Health, Bethesda, MD). The ImageJ plugin, Cell Counter, was used to 
aid counting.
Quantification of electroporated retinas
Confocal Z-stack images were taken of retina sections with dense expression of 
electroporation markers. Electroporated cells were marked by the presence of electroporated 
GFP, n-βgal (from CAG-nlacZ) or the combination of TagBFP and mCherry (driven from 
ChAG-loxP-tBFPL-loxP-mCherry cassette; combination is detected by a polyclonal TagRFP 
antibody that detects both TagBFP and mCherry). Cells expressing a given marker (ex. Y) 
were selected using ImageJ Cell Counter plug-in, and then evaluated for co-expression of a 
second marker of interest (ex. X). Counted number of the second marker were divided by 
selected number of cells expressing the given marker, and multiplied by 100 to get % of X+ 
cell given Y+ cell (ex. % X+/Y+). This general quantification scheme was also used for 
rAAV-infected tissues. To avoid counting green fluorescent DsRed molecules in GFP and 
DsRed colocalization analysis, we imaged for Anti-GFP expression in the blue or far red 
channel, and occasionally used the native GFP fluorescence as aid for determining GFP 
expression.
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Electroporated retina cells labeled by either n-βgal or TagBFP immunostaining were 
quantified for DsRed or mCherry fluorescence, respectively. Using ImageJ, a mask for the 
chosen cell body was created on the Anti-βgal or Anti-TagBFP channel and transferred to 
the DsRed or mCherry fluorescence channel, respectively. Measurements of the mean pixel 
intensity on single confocal slices were taken for the chosen cell bodies. Each measurement 
was paired with a background fluorescence intensity measurement from the same slice, 
chosen at a location in the slice where no cells were present. Each measurement was then 
subtracted from the background to obtain the net fluorescence, in arbitrary units (a.u.). We 
found mCherry to show slight aggregation in retinal cells, especially INL cell types. Thus, 
we avoided quantifying cellular regions with strong mCherry aggregation. To quantify 
fluorescence, we drew a shape circling the soma region with minimal aggregation in the 
confocal slice corresponding to the strongest mCherry fluorescence.
Quantification of rAAV-infected tissues
Confocal Z-stack images of rAAV-infected retinal, spinal cord, or brain samples were 
manually analyzed on ZEN or ImageJ for marker expression. For GFP-positive retinas, 
entire retinas were analyzed for tdT expression. For GFP-negative samples, tissue areas 
showing Cre-immunostaining were imaged and analyzed for tdT expression amongst Cre-
immunopositive cells.
To estimate the rough efficiency of labeling in brain infections, GFP+ cells in densely 
infected areas were counted, and the number of overlapping tdT+ cells was determined. The 
GFP-overlapping tdT+ cell count was divided by the number of counted GFP+ cells, and 
multiplied by 100 to obtain % tdT+/GFP+ parameter. For cerebellum, this analysis was 
performed in slices immunostained against GFP to enhance GFP brightness. To refine the 
efficiency measure in infected spinal cords and brains, we counted GFP cells that were 
immunostained with polyclonal Cre antibody, and determined the number of tdT+ cells 
overlapping with this GFP+,Cre+ cell population. The number of tdT+ cells overlapping 
with GFP+, Cre+ cells were divided by the total number of counted GFP+, Cre+ cells, and 
multiplied by 100 to obtain % tdT+/GFP+,Cre+ parameter. The efficiency in MLIs could not 
be quantified in this manner because the dense anti-Cre-staining of PC dendrites obscured 
MLIs in the cerebellar molecular layer. To estimate leak expression of tdT+ in GFP-negative 
animals, all or randomly selected cells immunopositive for Cre were counted, and then the 
number of overlapping tdT+ cells was determined. This measure provides an estimate of the 
percentage of Cre-expressing cells showing background CRE-DOG activity. The same 
calculation in GFP+ animals allows an estimate of induction.
Additional Quantifications
To determine GFP specificity CRE-DOG in electroporated and rAAV infected tissues, cells 
expressing the Cre-dependent reporter (tdT, DsRed or mCherry) were either randomly 
counted or counted in their entirety within an image. The number of overlapping GFP+ cells 
was then determined. This value was divided by the number of counted tdT+, DsRed+ or 
mCherry+ cells, and then multiplied by 100 to obtain % GFP+/tdT, GFP+/DsRed+ or GFP+/
mCherry+ parameter.
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A supplementary methods checklist is available.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. An optimized Cre recombinase dependent on GFP (CRE-DOGOPT)
(a) Schematic of CRE-DOGOPT action. (b) Schematic of chimeric constructs comprising 
CRE-DOGOPT. (c–e) Luciferase reporter assays in transfected 293T cells assessing CRE-
DOGOPT specificity for all components of the system (c), specificity for different fluorescent 
proteins (d) and dependency on GFP level (e). n=18 per condition for (c and d), n=6 or 9 for 
(e). (see Online Methods for n definition). Results are representative of at least three 
independent transfections. Boxplots indicate minimum to maximum range.
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Figure 2. CRE-DOGOPT can be delivered to the mouse retina for retrofitting transgenic GFP 
lines
(a–c) Electroporation of Tg(CRX-GFP) (a) and Tg(PROX1-GFP) (b) with plasmids 
encoding CRE-DOGOPT and the floxed reporter CALNL-DsRed (b) or ChAG-LtBFPL-
mCherry (c). CAG-nlacZ, which expresses n-βgal, was added as an electroporation marker 
in (b). (a) Schematic of electroporation experiment. (b–c) CRE-DOGOPT induced floxed 
reporter expression in Tg(CRX-GFP) (b) and Tg(PROX1-GFP) (c) retinas, but not in GFP-
negative retinas (b–c). Scale bar, 20 μm. Images representative of 3 or 4 retinas per 
condition. ONL, outer nuclear layer. INL, inner nuclear layer.
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Figure 3. rAAV delivery of CRE-DOGOPT to retinas of a GFP line
(a) Schematic of viral injection into the retina. (b) Expression of tdT in GFP+ retinal 
ganglion cells (RGCs). Arrows indicate tdT-positive cells. Scale bar, 20 μm. Images 
representative of 4 retinas. (c–d) Tracing of tdT+ RGC projections into the dorsal lateral 
geniculate nucleus (c) and superior colliculus (d). White dotted lines delineate boundary of 
the aforementioned visual pathway region. tdT fluorescence was boosted by 
immunostaining. Scale bar, 100 μm in whole region view, 50 μm in closeup view. Images 
representative of 3 brains.
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Figure 4. rAAV delivery of CRE-DOGOPT to the lumbar spinal cord of a GFP line labeling 
dorsal horn interneurons
(a) Schematic of viral injection into the spinal cord at lumbar level L3–5. Viruses were 
injected bilaterally into the spinal cord. (b,c) Sagittal lumbar sections of Tg(CBLN2-GFP) 
(b) and GFP-negative littermate (c) mice. (b) shows GFP antibody-boosted fluorescence 
(green, left panel), tdT (red, middle panel) and merged image (right panel). IB4 stain (blue) 
is in all panels and delineates lamina IIo. Arrowheads show obvious examples of GFP and 
tdT overlap. (c) shows Cre immunostaining (magenta, left panel) and tdT (right panel). 
DAPI (not shown) was used to delineate lamina II/III. Arrowheads show no tdT induction in 
Cre+ cells of GFP-negative animals. Scale bar: 100 μm. Images representative of 2 spinal 
cords per condition.
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Figure 5. rAAV delivery of CRE-DOGOPT to the motor cortex of GFP line
(a) Left: Schematic of viral injection into mouse motor cortex. rAAV-2/1 viruses were 
injected into the cortex at 4 weeks of age and brains were harvested 3 weeks post-injection. 
Right: coronal section of the mouse brain. (b) Quantifications including specificity and 
efficiency of CRE-DOGOPT labeling in cortical interneurons. (c) Coronal cortical section of 
Tg(GAD67-GFP) mouse infected with rAAV, showing GFP (green) and tdT (red) 
expression. Arrowheads indicate injection site. Cortical layers are indicated in GFP+ section. 
Scale bar, 1 mm. (d) CRE-DOGOPT induces tdT expression in Tg(GAD67-GFP) (top), but 
not in GFP-negative brains (bottom). Panels show GFP (green), Cre immunostaining (blue), 
tdT (red) and merged images of all three channels (right panels). Scale bar, 100 μm. Images 
in (c) and (d) are representative of 3 Tg(GAD67-GFP) and 2 GFP-negative brains. Plots 
show percentage of cells positive for a marker, given the presence of additional marker(s) 
(1st marker/2nd, 3rd marker). For GFP+/tdT+ and tdT+/GFP+ parameters, sample size are 
735 GFP+ cells, 475 tdT+ cells, 10 sections, 3 Tg(GAD67-GFP) animals), as well as 
quantification of Cre+ cells that express tdT, GFP, or both. Sample size: 371 GFP+ cells, 203 
tdT+ and 1238 Cre+ cells in 9 GFP+ sections, 3 Tg(GAD67-GFP)+ animals). 2560 Cre+ 
cells and 10 tdT+ cells were counted in 2 GFP-negative animals. Boxplots indicate 
minimum to maximum range.
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Figure 6. rAAV delivery of CRE-DOGOPT to the cerebellum of a GFP line
(a) Left: Schematic of viral injection into mouse cerebellum. rAAV-2/1 viruses were injected 
into lobule V and brains were harvested 3 weeks post-injection. Right: sagittal section of the 
cerebellar vermis with lobules labeled. (b) Sagittal section of Tg(GAD67-GFP)+ cerebellum 
(green) showing tdT (red) induction in injected lobule. Scale bar, 1 mm. (c) CRE-DOGOPT 
induces tdT expression in Tg(GAD67-GFP) (top), but not GFP-negative (bottom) cerebellar 
cortex. Panels show GFP (green), anti-Cre immunostaining (blue) and tdT (red) expression. 
Scale bar, 50 μm. (d–e) Quantification of infection outcome. Plots show percentage of cells 
positive for a marker, given the presence of additional marker(s) (1st marker/2nd, 3rd 
marker). (d) Quantification of tdT+ cells that are also GFP+ and/or Cre+. Sample size: 516 
GFP+, 422 Cre+ and 317 tdT+ cells in 7 sections. (e) Additional quantification of CRE-
DOG labeling. Sample size: 845 GFP+ and 368 tdT+ cells in 12 GFP+ sections. 643 Cre+ 
cells and 6 tdT+ cells were counted in 4 Gad– sections. PCs, Purkinje cells. MLIs, molecular 
layer interneurons. GLIs, granule layer interneurons. Boxplots indicate minimum to 
maximum range. All data and images reported are gathered from or representative of 4 
Tg(GAD-GFP)+ animals and 3 GFP-negative animals.
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Figure 7. CRE-DOGOPT allows optogenetic manipulation of GFP-labeled neurons
(a) Schematic of experiment. PC, Purkinje cell. MLI, molecular layer interneuron. (b–c) 
Expression of ChR2-tdT in lobule V/VI of parasagittal cerebellar slice(b) and at cellular 
level (c), in PCs and MLIs (marked by asterisk). Scale bar, 1mm in (b), 50 μm in (c). Note 
that ChR2-tdT labels membranes. (d–g) Optogenetic control of GFP-labeled cells within the 
cerebellar circuit. Cell-attached and whole cell recordings are aligned with blue light 
stimulation (blue vertical bars at top). (d) Light-evoked spikes (marked in red) in addition to 
spontaneous action potentials (black) in cell-attached recording, and underlying 
photocurrent in a whole-cell recording of the same cell (bottom trace) in ChR2-tdT+ PC 
(representative of n=9). Cells were voltage-clamped at the indicated potentials. (e) ChR2-tdT
+ MLI shows light-evoked spiking (top trace, red), photocurrent (middle trace) and 
inhibitory current (bottom trace) from stimulation of a synaptically connected MLI. The 
GABAA receptor antagonist SR95531 (5 μM) blocked inhibitory current (representative of 
n=5) (f) Example of GFP+/ tdT– PC (green) receiving inhibitory input from ChR2-tdT+ 
MLI. Activation of the ChR2-tdT+ MLI briefly inhibits PC spiking in cell-attached 
recording (top trace), bottom traces: light-evoked inhibitory current blocked by SR95531 
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(representative of n=4). (g) GFP–, tdT– cells (gray) do not respond to light stimulation 
(n=9). (h–i) Membrane resistance and spontaneous action potential (AP) frequency of tdT+ 
(also GFP+; n=8), tdT– (also GFP+; n=6) or GFP– (also tdT–; n=9) PCs are not different 
across conditions (p= 0.92 p=0.73, respectively, ANOVA) (h) and MLIs (n=6 each, p=0.87 
and p=0.81, respectively) (i). PC data were obtained from 4 GFP+ animals injected with 
CRE-DOG, and 1 injected GFP- animal. MLI data were obtained from 2 injected GFP+ 
animals. Scatter plots are mean +/− s.e.m.
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